title: Efficacy of atorvastatin therapy in ischaemic heart disease - effects on oxidized low-density lipoprotein and adiponectin.
abstract: The lipid-lowering and anti-atherosclerotic effects of atorvastatin (10 mg/day) were investigated by measuring changes in the levels of oxidized low-density lipoprotein (LDL), serum lipids (total cholesterol [TC], LDL-cholesterol [LDL-C] and triglycerides [TG]), and in the protein adiponectin. This was undertaken in 22 patients with ischaemic heart disease and serum LDL-C levels > 100 mg/dl. After 3 months of therapy, atorvastatin significantly decreased serum lipids, oxidized LDL was reduced from 457.0 +/- 148.6 to 286.9 +/- 88.5 nmol/l, and adiponectin increased from 9.7 +/- 7.4 to 13.9 +/- 9.98 microg/ml. No significant correlation was observed between adiponectin and LDL-C, TG and high-density lipoprotein cholesterol. Atorvastatin therapy was not associated with side-effects, such as myalgia and gastrointestinal disorders, and did not give abnormal laboratory test results. It is concluded that atorvastatin decreases serum lipid and oxidized LDL levels, and increases adiponectin levels in patients with ischaemic heart disease.
authors: Division of Cardiology, Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake, Japan.
authors: K
authors: K
authors: Miyagishima
authors: S
authors: S
authors: Hiramitsu
authors: S
authors: S
authors: Kato
authors: Y
authors: Y
authors: Kato
authors: F
authors: F
authors: Kitagawa
authors: R
authors: R
authors: Teradaira
authors: R
authors: R
authors: Shinohara
authors: K
authors: K
authors: Mori
authors: H
authors: H
authors: Kimura
authors: T
authors: T
authors: Ueda
authors: M
authors: M
authors: Ohtsuki
authors: S
authors: S
authors: Morimoto
authors: H
authors: H
authors: Hishida
mesh_terms: D052242:Adiponectin / Q000097:blood*; D000368:Aged; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D000069059:Atorvastatin; D008078:Cholesterol, LDL / Q000097:blood / Q000187:drug effects; D005260:Female; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D008077:Lipoproteins, LDL / Q000097:blood / Q000187:drug effects*; D008297:Male; D017202:Myocardial Ischemia / Q000097:blood / Q000188:drug therapy*; D010084:Oxidation-Reduction; D011758:Pyrroles / Q000627:therapeutic use*; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
chemical_list: D052242:Adiponectin; D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D006538:Heptanoic Acids; D008077:Lipoproteins, LDL; D011758:Pyrroles; D014280:Triglycerides; C099252:oxidized low density lipoprotein; D000069059:Atorvastatin